Pediatric Hematology-Oncology — Specialty Profile

Subspecialty fellowship of Pediatrics.

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-25.

Also called: peds heme/onc, PHO, pediatric oncology. A fellowship you enter after a pediatrics residency, rather than a residency you match into straight from medical school. Organ systems: blood and the immune/lymphatic system (hematology) plus childhood cancers of every tissue (oncology).

The 30-second version

Pediatric hematology-oncology is the field that cares for children with cancer and with blood disorders, and, by wide agreement, one of the most emotionally demanding and most meaningful things you can do with a medical career. You diagnose the leukemia, run the chemotherapy, manage the sickle-cell crisis and the bleeding disorder, sit with a family through the hardest news in medicine, and, far more often than a generation ago, walk that same child into a cure. The relationships run for years. The science is a live frontier. And the compensation, honestly, does not track the training: three extra fellowship years lead to pay below general pediatrics. That combination is the whole personality of the field: extraordinary meaning, real grief, rising cure rates, and a genuine pay paradox.

Quick dashboard (details and sources below)
Training after med school Peds residency (3) + Peds Heme/Onc fellowship (3) = 6 yrs after med school (7 with BMT/cellular-therapy year)
Total from college start ~14 years (4 undergrad + 4 med school + 3 peds residency + 3 fellowship)
Entry Two-step: match to pediatrics residency, then to fellowship via the NRMP Pediatric Specialties Match
Competitiveness (as a peds subspecialty) Moderate — 78.4% fill, right at the peds-subspecialty average, with ~0.81 applicants per position (NRMP SMS, 2026) ⟳
Typical full-time pay $255,733 average total comp (Survey · Doximity 2025) ⟳
The pay paradox Below general peds ($265,230) after 3 extra yrs; about half of adult oncology ($502,465) ⟳
Lifestyle Moderate control; swings with the service calendar; mostly home call
Burnout High — estimates up to ~75% in-field; grief is the defining occupational load ⟳
% women ~50% of active PHO physicians; ~55.7% (AAMC 2021); 69.5% of current fellows (ACGME AY2024-25) ⟳
DO / IMG accessibility Open — DO 16.4% of matched fellows and IMG 21.1% (NRMP SMS, 2026) ⟳

What they actually do

Pediatric hematologist-oncologists care for two overlapping worlds in one specialty: oncology (leukemias, lymphomas, brain and other CNS tumors, and solid tumors like sarcomas, neuroblastoma, and Wilms) and hematology (both malignant blood disease and non-malignant "benign/classical" hematology, covering sickle cell disease, hemophilia and bleeding or thrombosis, bone marrow failure, and the cytopenias).1 The work is cognitive, longitudinal, and evidence-driven rather than procedure-dense: revenue and daily effort come from clinic visits, chemotherapy and transfusion management, and inpatient care, and a very large share of children are treated on clinical-trial protocols, far more than in adult oncology, which is a major reason childhood cure rates have climbed so fast.23

A working attending's week blends several distinct settings: outpatient clinic (new diagnoses, chemo management, follow-up, survivorship, sickle-cell and bleeding-disorder clinics, the largest share of most careers); infusion / day-hospital supervising chemotherapy and transfusions; blocks of inpatient "on-service" weeks running the hospital cancer or bone-marrow-transplant ward (the most intense, hours-heavy part of the year); call, usually home call triaging febrile-neutropenic patients, new leukemia presentations, and sickle-cell crises; and substantial non-clinical time for research, trials, tumor boards, and teaching.1 Roughly 90% of the field practices inside academic children's hospitals, so trials, protocols, and institutional citizenship are baked into "the job."13

Representative work & procedures: bone marrow aspiration and biopsy · lumbar puncture with intrathecal chemotherapy · management of chemotherapy regimens and their toxicities · transfusion medicine · central-line-associated care · delivery and long-term follow-up of CAR-T cellular therapy and (with added training) bone-marrow/stem-cell transplant · goals-of-care and palliative conversations. Compared with surgical or adult-oncology practice, procedural volume is low; the mastery is diagnostic, longitudinal, and relational.41

A day in the life: On a clinic day you move between new-diagnosis conversations, kids mid-treatment ringing the "end of chemo" bell, survivorship checks, and a sickle-cell teenager in for pain management, with celebration and heaviness in the same hallway. On an on-service inpatient week the pace and emotional load rise: rounds on the cancer/BMT ward, managing complications, coordinating with surgery, radiation, and child-life, and being present for families through the worst days. Because you follow patients for years, you rarely wonder how the story ends, because you live it with them.

The training path & time to completion

This is a subspecialty with a two-step entry. You do not match into peds heme/onc from medical school. You first complete a pediatrics residency, then apply separately to fellowship through the NRMP Medicine and Pediatric Specialties Match (a fall match; results released in December).5

Medical school (4 yrs) → Pediatrics residency (3 yrs) → Pediatric Hematology-Oncology fellowship (3 yrs) → board-eligible with the American Board of Pediatrics (ABP).6

  • Fellowship is research-heavy: roughly 18 months of the 3-year fellowship are typically dedicated to scholarly/research activity, and a large share of graduates pursue academic careers.6
  • Board: the American Board of Pediatrics (ABP), through a subspecialty certificate in Pediatric Hematology-Oncology that requires prior ABP General Pediatrics certification.6
  • Optional extra year: a separate ACGME-accredited bone-marrow-transplant / cellular-therapy (HSCT) fellowship adds +1 year for those going deep into transplant and CAR-T.6
  • Total after med school: 6 years (3 + 3) to independent practice; 7 with the BMT year. From the start of college: ~14 years (~15 with BMT).6

How competitive is it? (as a peds subspecialty)

Two gates matter, and they feel different. Getting into pediatrics residency is the more accessible of the two, though the openness runs in one direction: pediatrics took 30.4% of its filled positions from international graduates in 2026 against 25.2% across all PGY-1 positions, and 21.1% from DOs against a 21.5% baseline, so it is a wide door for an IMG and an ordinary one for a DO.7 Getting into the fellowship is best described as moderately competitive and mission-driven: it fills above the peds-subspecialty average but is not hyper-competitive.

From the NRMP Pediatric Specialties Match, AY2026 (the fellowship match, results released Dec 2025):5

  • 75 programs · 194 positions offered · 152 filled → 78.4% fill rate, with 42 seats going empty; 28 programs finished with at least one unfilled position.5 ⟳
  • 158 applicants ranked PHO for 194 positions → ~0.81 applicants per position; 152 of those 158 matched into it, about 96%.5 ⟳
  • Composition of matched fellows: US MD 62.5% · DO 16.4% · US-IMG 7.2% · non-US IMG 13.8% (combined IMG 21.1%), of 152 filled.5 ⟳
  • Where it sits among peds subspecialties: the peds-subspecialty average fill rate was 78.3% in the same cycle, so PHO's 78.4% sits almost exactly at the average, well below Pediatric Cardiology (98.5%) and Pediatric Gastroenterology (96.0%) and well above Pediatric Nephrology (38.4%) and Pediatric Endocrinology (48.1%).5

The honest trend read: this is a field that needs people. One analysis found training positions grew ~37% from 2009–2025 while applicants grew only ~8%, dropping the applicant-to-position ratio from 1.01 to 0.80 and nearly doubling unfilled positions (13.4%→21.6%).8 Earlier, the 2021 match left ~44% of programs unfilled amid a smaller applicant pool.9 The takeaway for a premed: if the mission genuinely fits you, entry is reachable: determination and fit count, and you will be wanted. (See the FLI angle for why the same math cuts two ways.) ⟳

Compensation — the robust version, and the pay paradox

Peds heme/onc is one of the clearest examples in all of medicine of the pediatric-subspecialty pay paradox: despite three additional fellowship years beyond general pediatrics, physicians in the field typically earn about the same as a general pediatrician or less, and dramatically less than an adult hematologist-oncologist doing structurally similar work. This is exactly the kind of hidden context a premed would never pick up from a specialty list.

A note on sources first: this is a small workforce (~2,100–2,300 US physicians), so clean public percentile tables are scarce. The authoritative academic benchmarks (MGMA DataDive, the AAMC Faculty Salary Report) are paywalled, and job-board aggregators are unreliable for this niche.1011 Doximity's 2025 report publishes a pediatric hematology and oncology line directly, and that is the anchor below. The Physician Side Gigs self-report is kept only to show the shape of the spread.1012

National number. $255,733 average annual compensation (Doximity 2025, reporting 2024 earnings from about 37,000 physicians). That places PHO in the lower half of the pediatric lines Doximity publishes, under neonatology ($354,841), pediatric cardiology ($352,197), pediatric emergency medicine ($312,271), and pediatric gastroenterology ($298,457), and above pediatric infectious disease ($248,322), rheumatology ($231,574), and endocrinology ($230,426).12 ⟳

The paradox in three comparisons:

  • vs. general pediatrics (the baseline): general peds averages $265,230 on the same Doximity table (+2.2% YoY), with a BLS wage mean of $212,110 (May 2025). Peds heme/onc comes in at $255,733, about $9,500 a year under the generalist base you already trained past, after three extra years of fellowship. Nephrology, rheumatology, infectious disease, and endocrinology land under general peds too.1312 ⟳
  • vs. adult heme/onc (the sharp contrast): adult heme/onc averages ~$472,000 (Medscape 2025) to $502,465 (Doximity 2025), which is upper-tier physician pay. Doximity quantifies the gap starkly: adult oncology pays roughly 96% more than pediatric heme/onc, the largest peds-versus-adult differential Doximity reports.1214 ⟳
  • Why the gap exists (not a mystery, and not anyone's fault): peds heme/onc is cognitive, longitudinal, and low-procedural-volume; childhood cancer is rare so patient volumes are low; the payer mix skews Medicaid; and the work lives inside nonprofit academic children's hospitals. Adult medical oncology, by contrast, captures large in-office infusion / drug "buy-and-bill" margins and high patient volumes that pediatrics simply doesn't generate.1012

The spread (structure). No public percentile table exists for PHO. Physician Side Gigs, a self-selected self-report rather than a compensation survey, runs from ~$130,000 to ~$350,000 with a median of $217,500, and it is shown here for the width of the field rather than as a level.10 The high end reflects senior division chiefs, endowed chairs, and heavy clinical/leadership loads at large centers; the low end reflects early-career physician-scientists with protected research time, where a portion of salary is grant-offset and constrained by the NIH salary cap.1015 A clean 10/25/50/75/90 percentile table isn't public, and the MGMA and AAMC tables that would settle it sit behind paywalls. Secondary summaries of them put the median around $225k–$260k with a 90th percentile near $330k–$360k.10 ⟳

Starting vs. experienced. First attending jobs (usually Assistant Professor) generally run ~$185,000–$230,000, below both the field average and the general-peds level, sometimes with salary tied to protected research time. Senior roles (Associate/Full Professor, division chief, medical director) run ~$280,000–$350,000+.1015 Because pay is largely salary-based (not RVU-productivity-based), the starting-to-experienced spread is compressed relative to procedural fields, and seniority, grants, and administrative titles drive raises more than clinical volume. The bands above blend the Physician Side Gigs range with academic salary norms rather than coming from one survey. ⟳

Geography. Variation is modest and hard to pin down for so small a workforce; jobs cluster in metros with children's hospitals and NCI-designated pediatric cancer centers (Memphis/St. Jude, Boston, Philadelphia/CHOP, Houston/Texas Children's, Cincinnati, Seattle, Columbus, LA). Because pay is benchmark/salary-driven rather than collections-driven, it is not highest in high-cost coastal metros, and midwestern or southern academic centers often pay comparably or better after cost of living. Aggregator "top-paying city" lists for this niche are noise, and the picture here is read off Doximity's metro patterns rather than off PHO-specific geographic data.1011 ⟳

Employment model. Overwhelmingly academic and children's-hospital-employed, on a W-2 salaried faculty appointment with an academic rank, base salary plus a modest incentive, benchmarked to AAMC/MGMA, with limited wRVU upside. Private practice is rare, and that scarcity is itself a structural reason pay stays low: there's little competitive market pulling salaries up. Multi-institutional cooperative-group care (Children's Oncology Group) is the norm for trials.11

Physician-scientist track. A large share of faculty are physician-scientists with 50–80% protected research time, funded by NIH K-awards (K08/K23), R01s, and foundation grants (ASH, St. Baldrick's, Alex's Lemonade Stand). These roles often pay at or below the pure-clinical figure early on, and the trade-off is career capital (lab work in immunotherapy, cell and gene therapy, leadership) rather than cash.15

The trend that colors all of it. CAR-T (tisagenlecleucel, first approved 2017 for relapsed/refractory pediatric B-cell ALL) and December-2023 gene therapies for sickle cell disease (Casgevy and Lyfgenia, ≥12 years) have raised the field's clinical complexity, infrastructure burden, and demand, but have not closed the compensation gap, because that revenue accrues to the institution and to pharma rather than to professional fees. Pediatric pay broadly has lost ground to inflation since 2017, and advocacy groups (AAP, ASPHO) keep pushing for loan forgiveness and better pediatric-subspecialty reimbursement.161712

Lifestyle & the service-calendar rhythm

Schedule control: moderate. Better than many surgical or high-acuity adult fields, worse than pure-outpatient general pediatrics, and it swings hard with the service calendar. Many programs concentrate inpatient attending duty into blocks (e.g., ~8–16 weeks/year); on-service weeks are long and emotionally saturated, while off-service stretches feel like a manageable subspecialty clinic job.1 Call is often home call with phone triage, spread across a division so frequency is moderate rather than punishing. Advanced practice providers now deliver a large share of clinical care (~47%, up from ~40% in 2012), which absorbs some load.1

A meaningful, honest trend: newer trainees increasingly seek "clinic-heavy," flexibility-first positions over traditional research-heavy academic tracks, a sign the field is adapting to lifestyle preferences.1

Lifestyle rating: 3/5. Moderate control, with predictability that depends heavily on where you fall in the service calendar and how much protected/academic time your role carries.

Wellbeing — the part to take seriously (and with care)

This section deserves particular honesty and dignity, because the emotional core of peds heme/onc is not like other specialties.

Burnout is real and high. Estimates of burnout symptoms among peds heme/onc practitioners run as high as ~75%, driven by emotional demands, complex trial/regulatory work, and EHR/administrative burden.1 A US cross-sectional study found compassion fatigue tracked with higher burnout and clinical distress, while strong social connection at work and home, exercise, and compassion satisfaction were protective.18 Broader physician burnout eased to 41.9% in 2025 on the AMA's Organizational Biopsy, which publishes no pediatric-hematology-oncology row, and pediatric and oncology-adjacent fields remain among the more affected.19 ⟳

But meaning and satisfaction are unusually high. The same forces that exhaust also sustain. "Compassion satisfaction," the fulfillment of caring well, is a documented buffer, and would-choose-again sentiment is strong precisely because the work is felt to matter. Many practitioners describe it as the most meaningful thing they could do with a medical career.181

The emotional weight is the defining feature, said plainly rather than melodramatically. These physicians form years-long relationships with children and families, walk with them through the hardest news in medicine, and, despite dramatic progress, still lose some patients. Research on grief among pediatric oncologists documents that patient deaths produce lasting personal grief that can intrude on work and home, and that clinicians often feel under-supported and under-trained for it.20 The increasingly common and humane reframe: compassion fatigue is evidence of caring deeply rather than weakness.21 Programs are building in debriefs, peer support, and bereavement resources because sustaining the workforce requires acknowledging that clinicians grieve too.2223

The hopeful side, offered honestly rather than as consolation. This is genuinely one of oncology's great success stories. Overall childhood-cancer 5-year survival has risen from ~58% in the mid-1970s to roughly 85% today, and childhood ALL, once nearly uniformly fatal, now has ~90% 5-year survival.2425 Most peds heme/onc physicians will cure the large majority of the children they treat, a very different emotional ledger than adult oncology of a generation ago. The grief is real; so is the healing.

Career longevity depends heavily on the protective factors above (connection, exercise, meaning, institutional support) and on grief/peer-support structures; studies of pediatric oncologists' stress-resilience find most maintain high overall life satisfaction and motivation despite emotional distress.2318

Who's in the field (demographics)

  • Women: among the most female-represented oncology fields, at ~50% of active PHO physicians (2021), up from 44% (2017) and 41% (2015); ~53% of newly board-certified PHO physicians since 1988 have been women; AAMC lists pediatric hematology/oncology at ~55.7% women (2021). The fellow class runs further ahead of that: ACGME counts 333 of 479 active PHO fellows as women in AY2024-25, 69.5%, close to pediatrics overall.262728 ⟳
  • DO: 16.4% of matched fellows, 25 of 152 (AY2026).5 ⟳
  • IMG: 21.1% combined, 32 of 152 (US-IMG 7.2% + non-US 13.8%), so roughly one matched fellow in five trained abroad (AY2026).5 ⟳
  • Race/ethnicity: among PHO physicians surveyed (2021), ~67% White, ~19% Asian; URiM (Black, Hispanic/Latino, Native American) representation is low relative to the pediatric patient population, and ASPHO does not publish a single clean URiM percentage.2629 ⟳

Culture, personality & the online stereotypes

Who gravitates here: people who are deeply mission-driven (they chose this knowing the pay and the pain); emotionally resilient and able to sit with grief and uncertainty; research- and evidence-minded (peds cancer care is trial-driven); oriented toward long-term relationships (you follow families for years, sometimes into survivorship or through end of life); and willing to have the hardest conversations in medicine, repeatedly, with compassion and clarity. As always, plenty of people in the field do not fit any single mold.1

The stereotypes. Contested online perceptions rather than facts, each with a humanizing counterpoint:

  • "The most heartbreaking and the most meaningful specialty." A real duality, but it flattens the day-to-day: much of the work is longitudinal chronic-disease management and celebrating cures rather than a continuous stream of tragedy.1
  • "You have to be a saint / a special kind of person." Well-meant but othering. Practitioners describe themselves as ordinary people who learned skills and lean on teams and support structures rather than as martyrs.1
  • "Fellowship into a pay cut for the mission." Points at a real financial truth (above), but caricatures it: compensation is modest relative to effort rather than a vow of poverty, and it varies by setting.1
  • "It'll break you / no one lasts." Contested: burnout is high, but many have long, sustaining careers, and the field's satisfaction scores undercut the doom narrative.1

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums the tone is reverent and protective rather than cynical. Recurring themes: awe at the emotional strength of the people who do it; candid warnings that the grief is heavier than outsiders expect and that self-selection matters enormously; frequent discussion of the "3 extra years for little or no pay bump" math and how differently it lands depending on debt; and a running counter-current that benign/classical hematology (sickle cell, hemophilia, thrombosis) offers strong job prospects, arguably better lifestyle, and less relentless mortality than solid-tumor and leukemia work, and is under-chosen relative to demand. The through-line: people who enter with eyes open, for the mission.30

Voices from the field. Paraphrased from public writing, with links to the originals:

  • A pediatric oncologist writing for KevinMD frames grief as "the price of caring deeply": some losses stay permanently, training under-prepares physicians for the psychological weight, and the goal is to let love remain larger than the loss.21
  • A KevinMD analysis argues the pediatric-oncology workforce shortage is widening, with training positions up ~37% (2009–2025) while applicants grew only ~8%, and ties retention problems partly to lower compensation relative to workload and limited institutional support.8
  • The ASPHO workforce assessment maps the field's small size, heavy academic concentration, geographic maldistribution, and evolving fellowship patterns.31
  • A Seattle Children's care-team piece is an institutional acknowledgment that clinicians grieve too, and that structured bereavement and peer support are part of sustaining the workforce.22

Why people choose it / why people leave

Why choose it: arguably the deepest sense of meaning available in medicine, since you help children survive, or help families through the unthinkable with dignity · long-term relationships across the whole arc of care · a genuine scientific frontier (trials, immunotherapy, cellular and gene therapy, steadily rising cure rates) · strong and growing demand, since the field needs people and generally isn't hard to enter · team-based, mission-aligned culture · ~90% nonprofit-academic employment makes PSLF loan forgiveness especially valuable.

Why leave or avoid it: the emotional weight is real, cumulative, and not for everyone, and grief and compassion fatigue are occupational hazards · high burnout · long training (6 years post-MD, more with a sub-subspecialty) for modest financial return · heavily academic (trials, grants, administration, EHR) which not everyone wants · geographically constrained, with jobs clustered in metro children's hospitals.

Best fit if: you feel called to this specific work and have thought hard about the grief · you want longitudinal relationships and are energized (not only drained) by hard conversations · you like evidence/trial-driven, academic medicine · you value meaning and demand over maximizing income · (for benign heme) you want a chronic-care, better-lifestyle, high-demand niche.

Not for you if: you're seeking high income or a fast route to financial stability, especially with heavy debt · you struggle to compartmentalize, or find repeated loss corrosive rather than survivable · you want a purely outpatient, low-acuity, predictable schedule · you dislike academic/research/administrative obligations · you need geographic flexibility across small towns and rural areas.

The FLI angle — Pediatric Heme/Onc for first-gen, low-income & immigrant students

The genuinely encouraging part. Peds heme/onc is reachable for FLI students. The route runs through general pediatrics, among the more accessible residencies, and the fellowship is not fiercely competitive to enter (the field currently has more positions than applicants, with unfilled spots rising).85 If mission fit is what drives you, this is a field where determination and heart count enormously, demand is high and rising, and you will be wanted. For a student motivated by service and impact, few fields offer a clearer sense that the work matters.

The honest, important catch, named squarely. This is the one place FLI students must go in with open eyes. Peds heme/onc requires three extra years of fellowship after residency and then pays less than general pediatrics ($255,733 vs. $265,230), and roughly half of adult oncology.12 ⟳ Multiple sources describe "little opportunity for positive financial return" versus general peds and "lower compensation relative to workload."18 On a per-hour, whole-career basis, after three additional years of fellowship-level pay and delayed attending earnings, the math can be flat or negative compared with simply practicing general pediatrics.

Why this matters specifically, said with care. If you're carrying significant loans and may be helping support family, this is a real financial decision rather than a footnote. Three extra years of training with no reliable pay premium means three more years of deferred earning and continued debt accrual, entering a field where compensation won't leapfrog your peers. That does not mean don't do it. Plenty of FLI physicians build stable, comfortable lives here, and federal PSLF loan forgiveness is especially valuable because ~90% of jobs are at nonprofit academic children's hospitals (a strong reason to understand PSLF early).11 It means: choose it because the mission genuinely moves you, run the numbers honestly (including PSLF and benign-heme's stronger job market), and don't let anyone frame the tradeoff as trivial. It is real, and you deserve to weigh it clearly rather than discover it later.

Bottom line: peds heme/onc is genuinely reachable for an FLI student, through an accessible residency into a fellowship with more positions than applicants, and it is one of the few fields where three extra years of training buys no pay premium over general pediatrics. PSLF matters more here than almost anywhere, because roughly 90% of the jobs are at nonprofit children's hospitals. Choose it for the work, with the arithmetic in front of you.

Subspecialties & sub-focuses within the field

Peds heme/onc is really an umbrella; the day-to-day life and emotional texture differ a lot by focus.32

  • BMT / cellular therapy (HSCT). Highest-acuity, most inpatient-heavy, most critically ill patients (transplant, CAR-T); intense, high-stakes, high-reward, the hardest lifestyle. This is the one that adds a formal +1 fellowship year.
  • Neuro-oncology. Brain/CNS tumors; heavy multidisciplinary coordination; some of the most difficult prognoses.
  • Solid tumor. Sarcomas, neuroblastoma, Wilms, etc.; protocol- and surgery/radiation-coordinated.
  • Leukemia / lymphoma. The archetypal peds onc practice; strong cure rates for ALL.
  • Benign / classical hematology. Sickle cell disease, hemophilia and bleeding/thrombosis, bone marrow failure, iron and cytopenias. Chronic longitudinal care rather than acute mortality, with generally better lifestyle and notably strong, unmet job demand. Yet under 10% of fellows target it, which makes it a strategic sweet spot.1

Fun facts

  • It's a small specialty of only roughly 2,100–2,300 active US physicians, so the community is tight-knit and people tend to know one another.1
  • Childhood ALL went from a near-universally fatal disease to ~90% 5-year survival within a few decades, one of the signature achievements of modern medicine.25
  • It's among the most female-represented oncology fields: women are roughly 50–56% of practicing physicians depending on which count you take, and 69.5% of the current fellow class.262728
  • Around 90% of the field practices in academic children's hospitals, an unusually high concentration for any specialty.1
  • A very large share of pediatric cancer patients are treated on clinical trials, far more than in adult oncology, which is a major reason cure rates climbed so fast.2
  • It's counter-cyclical to normal medicine economics: one of the few fields where an extra fellowship can leave lifetime earnings flat or lower than the base specialty (general pediatrics).1012

Sources

Footnotes

  1. Field overview, lifestyle structure, burnout (~75%), workforce size (~2,100–2,300), ~90% academic, ~50% women, APP share (~47%), benign-heme demand, and stereotypes. ASH Clinical News, "Pediatric Hematology/Oncology: A Small Specialty Experiencing Big Changes" (2018). https://ashpublications.org/ashclinicalnews/news/4808/Pediatric-Hematology-Oncology-A-Small-Specialty ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18

  2. Large share of pediatric cancer patients treated on clinical-trial protocols (vs. adult oncology). ASH Clinical News (2018), same URL as 1; corroborated by NCI childhood-cancer materials (see 24). ↩ ↩2

  3. Academic concentration and trial-embedded practice model; Children's Oncology Group cooperative care. ASH Clinical News (2018), 1; Physician Side Gigs compensation report (2023–24), 10. ↩ ↩2

  4. CAR-T and cellular-therapy delivery concentrated at certified academic centers; procedural/complexity context. Peds heme/onc compensation report (2026), Physician Side Gigs and gene/cell-therapy sources (see 10, 16). ↩

  5. NRMP, Results and Data: Specialties Matching Service 2026 Appointment Year, February 2026, Tables 1A–1D: PHO 75 programs, 194 positions offered, 152 filled (78.4%), 158 applicants, 28 programs with at least one unfilled position; matched composition US MD 95 / US DO 25 / US-IMG 11 / non-US IMG 21. https://www.nrmp.org/wp-content/uploads/2026/02/SMS_Results_and_Data_Report2026.pdf (2026). Correction, 2026-08-13: every figure this footnote previously carried — 84 programs, 143 positions, 124 filled, 86.7%, 137 applicants, MD 80.6% / DO 14.5% — belongs to Pediatric Hospital Medicine, whose row sits directly below PHO's in the same table. The tell is "69 of 84 programs filled all positions": PHM has 83 programs and 14 with unfilled seats. PHO's real unfilled count is 42 rather than 19. Corrected 2026-08-17: that correction reached this footnote and the dashboard and never reached three body lines, which went on printing Pediatric Hospital Medicine's percentages as PHO's in the competitiveness section and in both demographics bullets. The IMG figure was the costly one: it understated PHO's actual 21.1% by more than four times, on a page whose whole argument is that the field needs applicants. Every share on the page is now US MD 62.5% / DO 16.4% / US-IMG 7.2% / non-US IMG 13.8% of 152 filled, matching Table 2. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  6. Training pathway (4+3+3, +1 BMT), ~18 mo research, and ABP subspecialty certification (requires prior ABP General Pediatrics). American Board of Pediatrics, "Pediatric Hematology-Oncology Certification." https://www.abp.org/subspecialties/pediatric-hematology-oncology ; ACGME program search https://apps.acgme.org/ads/Public ↩ ↩2 ↩3 ↩4 ↩5

  7. The pediatrics residency front door, by applicant type. NRMP, Results and Data: 2026 Main Residency Match, Table 2: pediatrics (categorical) offered 3,126 positions and filled 2,951. Of those filled, 623 went to US DO seniors and graduates (21.1%) and 897 to IMGs, US-citizen and non-US combined (30.4%). The all-PGY-1 baselines in the same table are 21.5% DO and 25.2% IMG of 38,354 filled positions, so pediatrics is at the DO average and well above it on IMG. https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf Swept 2026-08-17: DO 21.1% and IMG 30.4%, both over the 2,951 positions filled, from Table 2 of that report. This footnote read "DO ~18% of peds PGY-1 positions; peds among more accessible entries" and cited the NRMP match-data landing page rather than a report, so neither claim could be checked; ~18% matches no cycle from 2022 to 2026 on either denominator. The sentence citing it called pediatrics open for DO and IMG applicants alike, and on these numbers only the IMG half holds. Peds heme-onc's own fellowship shares are separate and are in the dashboard's source. ↩

  8. Widening workforce shortage — positions +37% vs. applicants +8% (2009–2025), ratio 1.01→0.80, unfilled 13.4%→21.6%; retention tied to pay/workload. Danielle Fragalla, "The pediatric oncology workforce shortage is widening," KevinMD (2026). https://kevinmd.com/2026/06/the-pediatric-oncology-workforce-shortage-is-widening.html ↩ ↩2 ↩3 ↩4

  9. Leung et al., "Recent trends in Pediatric Hematology Oncology fellowship match and the workforce impact," Pediatric Research (2021) — ~44% programs unfilled in 2021 match. https://www.nature.com/articles/s41390-021-01505-7?error=cookies_not_supported&code=21edade1-9300-4881-a282-288f6a0dbaca ; long-term match trends: Hashmi et al., Pediatric Blood & Cancer (2025), https://onlinelibrary.wiley.com/doi/10.1002/pbc.32070 (per-year figures are in the full text). ↩

  10. Physician Side Gigs — Average Salary for Pediatric Specialties (2023–24, self-reported): peds heme/onc avg ~$220,000, median $217,500, range $130k–$350k. Correction, 2026-08-13: this page previously used the ~$220,000 Physician Side Gigs average as its headline national number, in the dashboard, the compensation section, the general-peds comparison, the figure caption and the FLI section. Physician Side Gigs is a self-selected self-report, and Doximity's 2025 Physician Compensation Report publishes a pediatric hematology and oncology line directly ($255,733), so the survey figure is now the anchor and Physician Side Gigs is kept only to describe the spread. https://www.physiciansidegigs.com/average-salary-for-pediatric-specialties ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11

  11. Employment model (overwhelmingly W-2 academic, private practice rare) and geographic clustering; aggregator unreliability. Physician Side Gigs (2023–24), 10; ZipRecruiter aggregator (July 2026, low reliability) https://www.ziprecruiter.com/Salaries/Pediatric-Hematology-Oncology-Salary ; AAMC Faculty Salary Report (paywalled) https://www.aamc.org/data-reports/workforce/report/aamc-faculty-salary-report ↩ ↩2 ↩3 ↩4

  12. Doximity, 2025 Physician Compensation Report (published 2025; reports 2024 earnings from ~37,000 US physicians) — pediatric hematology & oncology $255,733; general pediatrics $265,230 (+2.2%); neonatology/perinatology $354,841; pediatric cardiology $352,197; pediatric emergency medicine $312,271; pediatric gastroenterology $298,457; pediatric infectious disease $248,322; pediatric rheumatology $231,574; pediatric endocrinology $230,426; adult oncology $502,465. Adult oncology therefore pays about 96% more than pediatric heme/onc, the largest peds-versus-adult differential in the report. Companion piece "Pediatric Care Continues to Feel the Strain" covers the real-income decline since 2017. Correction, 2026-08-13: this footnote and the body sentence above it both stated the gap backwards. "96% less" would put a peds oncologist near $20,000. https://opmed.doximity.com/articles/despite-a-small-bump-in-pay-pediatric-care-continues-to-feel-the-strain ; https://www.doximity.com/reports/physician-compensation-report/2025 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  13. BLS OEWS, "Pediatricians, General" (SOC 29-1221), May 2025 mean annual wage $212,110 on employment of 39,390, with a median of $210,040. US Bureau of Labor Statistics, Occupational Employment and Wages — May 2025, Table 1 (https://www.bls.gov/news.release/archives/ocwage_05152026.htm). SalaryDr restatement https://www.salarydr.com/careers/pediatrics SalaryDr panel size: n=263. A self-selected physician panel; the n is disclosed here because it is what the figure rests on. Corrected 2026-08-17: this line gave a BLS median of $210,130 for general pediatrics. That number is not in the May 2024 release, which publishes a median hourly wage for the occupation and a mean annual wage of $222,340; $210,130 arrived through a restatement. The comparison now uses the mean the Bureau publishes. It moves the BLS floor up by about $12,000 and narrows the gap to the Doximity general-pediatrics average, and the pay paradox this section describes is measured inside Doximity's own table rather than against BLS, so the argument is unchanged. Updated 2026-08-18, and correcting the record above. The May 2024 release does publish an annual median for this occupation, $210,130, which is the figure the 2026-08-17 note said was not in it. General pediatrics was one of the few physician rows whose median fell below the point at which that release stopped publishing a value, so it printed where the higher-paid rows did not. The comparison still uses the mean, for consistency with the other BLS figures on this site, and the numbers here are now May 2025: a mean of $212,110 and a median of $210,040, both down slightly on May 2024. ↩

  14. Adult heme/onc benchmarks: Medscape 2025 ~$472,000; Doximity 2025 $502,465; Merritt Hawkins 2024 $490,000. Barton Associates, Oncologist/Hematologist Salary Guide (2025–26). https://www.bartonassociates.com/oncologist-hematologist-salary-guide/ ↩

  15. Physician-scientist tracks (50–80% protected time; K-awards/R01s; NIH salary cap constraining early-career pay) and starting-vs-experienced spread. Composite of the Physician Side Gigs range 10 and academic norms; the mechanism is established, and the exact figures do not come from a single primary source. ↩ ↩2 ↩3

  16. CAR-T (tisagenlecleucel/Kymriah, first approved 2017 for relapsed/refractory pediatric B-ALL) — complexity/infrastructure rose without raising professional-fee comp. Physician Side Gigs compensation report (2023–24), 10. ↩ ↩2

  17. Gene therapy for sickle cell disease — FDA approved Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) Dec 2023 for patients ≥12. https://pmc.ncbi.nlm.nih.gov/articles/PMC11374260/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC11736165/ ; https://www.childrens.com/research-innovation/research-library/research-details/new-gene-therapies-change-outcomes-for-rare-blood-disorders ↩

  18. Roth et al., "A Cross-sectional Analysis of Compassion Fatigue, Burnout, and Compassion Satisfaction in Pediatric Hematology-Oncology Physicians in the United States," J Pediatr Hematol Oncol (2019). https://pubmed.ncbi.nlm.nih.gov/31259831/ ↩ ↩2 ↩3

  19. AMA / FierceHealthcare, "Physician burnout falls for third year in 2025 to 42%" (2025). https://www.fiercehealthcare.com/providers/physician-burnout-falls-third-year-2025-419-american-medical-association ↩

  20. Granek et al., "Grief Reactions and Impact of Patient Death on Pediatric Oncologists," Pediatric Blood & Cancer (2015). https://www.ovid.com/journals/pedbc/abstract/10.1002/pbc.25228~grief-reactions-and-impact-of-patient-death-on-pediatric?redirectionsource=fulltextview ↩

  21. Rachel Jin, MD, "Oncology grief is the price of caring deeply for patients," KevinMD (2026). https://kevinmd.com/2026/06/oncology-grief-is-the-price-of-caring-deeply-for-patients.html ↩ ↩2

  22. Seattle Children's, "We Grieve, Too." https://www.seattlechildrens.org/healthy-tides/we-grieve-too/ ↩ ↩2

  23. Stenmarker et al., "Stress-resilience capacity of pediatric oncologists," Pediatric Blood & Cancer (2009). https://onlinelibrary.wiley.com/doi/10.1002/pbc.21849 ↩ ↩2

  24. National Cancer Institute, "Cancer in Children and Adolescents" fact sheet (2013–2019 survival data) — overall childhood-cancer 5-yr survival ~58% (mid-1970s) → ~85% today. https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet ↩ ↩2

  25. American Cancer Society, "Survival Rates for Childhood Leukemia" (2024) — childhood ALL ~90% 5-yr survival. https://www.cancer.org/cancer/types/leukemia-in-children/detection-diagnosis-staging/survival-rates.html ↩ ↩2

  26. ASPHO Workforce, Productivity & Fellowship Assessment (Hastings et al., 2023) — ~50% women (2021), up from 44% (2017)/41% (2015); ~67% White, ~19% Asian among PHO physicians. http://aspho.org/uploads/Final_Publication_2023__ASPHO_workforce_productivity_and_fellowship_assessment.pdf ↩ ↩2 ↩3

  27. AAMC Physician Specialty Data Report — pediatric hematology/oncology ~55.7% women (2021 data). https://web.archive.org/web/20250112142220/https://www.aamc.org/data-reports/workforce/data/active-physicians-sex-specialty-2021 ↩ ↩2

  28. ~53% of newly board-certified PHO physicians women since 1988. ASH Clinical News (2018), 1; ABP subspecialty fellows dashboard: https://www.abp.org/research/residency-and-fellowship-statistics. Current fellow class: ACGME, Data Resource Book AY2024-25, Table C.21 (Active Residents by Specialty and Subspecialty and Sex) — pediatric hematology/oncology, 79 programs, 479 fellows, 333 women (69.5%), 144 men (30.1%), 2 not reported (0.4%), https://www.acgme.org/about/publications-and-resources/graduate-medical-education-data-resource-book/. Corrected 2026-08-17: the Fun facts band said women are "roughly 45–50% of practitioners," and two of the three figures this page cites sit outside it — 53% of new diplomates and AAMC's 55.7%. The band now runs 50–56% and contains all three. The demographics bullet also estimated the trainee share as "consistent with pediatrics overall being ~70%+ female" when ACGME publishes it in a free table; it is 69.5%, so the estimate was close and is now a count. ↩ ↩2

  29. URiM representation low relative to pediatric patient population; no clean single URiM % published. ASPHO 2023 assessment 26; AAP, "Child Health Needs and the Pediatric Hematology-Oncology Workforce: 2020–2040," Pediatrics (2024, access-gated). https://doi.org/10.1542/peds.2023-063678L ↩

  30. Synthesized, paraphrased sentiment from r/pediatrics, r/medicalschool, and SDN — general tenor of public discussion; no individual posts quoted. ↩

  31. ASPHO / Hord et al., "The American Society of Pediatric Hematology/Oncology workforce assessment, Parts 1 & 2," Pediatric Blood & Cancer (2017). https://pubmed.ncbi.nlm.nih.gov/29068564/ and https://pubmed.ncbi.nlm.nih.gov/29068565/ ↩

  32. Sub-focuses within peds heme/onc (BMT/cellular therapy, neuro-oncology, solid tumor, leukemia/lymphoma, benign/classical hematology) and their differing lifestyle/emotional texture; benign-heme demand under-chosen. ASH Clinical News (2018), 1. ↩

Researched with AI assistance and reviewed by hand. How this site is made